Erythromycin

Introduction and Purpose of Neonatal Eye Prophylaxis

Neonatal eye prophylaxis is a routine public health intervention designed to protect newborns from severe ocular infections acquired during passage through the birth canal. The primary target of this preventive care is ophthalmia neonatorum, a purulent conjunctivitis that develops within the first month of life. Midwives play a frontline role in administering this prophylactic treatment immediately after birth to prevent irreversible corneal damage and potential blindness.

Target Pathogens: Neisseria gonorrhoeae and Chlamydia trachomatis

The birth canal can harbor sexually transmitted infections that are readily transmitted to the neonate's eyes during delivery.

• Neisseria gonorrhoeae: A Gram-negative diplococcus responsible for hyperacute purulent conjunctivitis that can perforate the cornea within hours if neglected.
• Chlamydia trachomatis: An intracellular bacterium causing inclusion conjunctivitis, typically presenting with a delayed onset of watery or mucopurulent discharge within one to two weeks postpartum.

Pharmacology: Mechanism of Action and Spectrum of Activity

Erythromycin is a macrolide antibiotic that exerts its bacteriostatic effect by reversibly binding to the 50S ribosomal subunit of susceptible microorganisms, thereby inhibiting bacterial protein synthesis. In the context of neonatal eye prophylaxis, 0.5% erythromycin ophthalmic ointment provides broad coverage against Gram-positive cocci and key Gram-negative organisms associated with birth canal transmission. Unlike older silver nitrate preparations, erythromycin rarely causes severe chemical conjunctivitis, making it a well-tolerated choice for neonates.

Correct Administration Technique in the Newborn

Proper instillation ensures the ointment reaches the conjunctival sac effectively without contaminating the tube tip. Midwives should execute the following steps:

1. Hand Hygiene: Wash hands thoroughly and put on clean gloves.
2. Eye Cleansing: Gently wipe each eyelid and lash from the inner to the outer canthus using a sterile cotton ball moistened with sterile water.
3. Exposure: Hold the infant's head gently and pull down the lower lid to form a small pocket.
4. Application: Squeeze a thin ribbon of erythromycin ointment (about 1 cm) along the entire inner border of the lower conjunctival sac, moving from the inner corner outward.
5. Distribution: Release the eyelid and allow the newborn to blink; gently massage the closed eyelid for a few seconds to distribute the medication.
6. Wipe Excess: Carefully wipe away any surplus ointment from the outer lids using a clean sterile gauze, but do not rinse the eye.

Timing and Protocols in Nigerian Clinical Practice

Timing is critical for the efficacy of neonatal prophylaxis. Current standard guidelines recommend administration within the first hour following birth, after the initial stabilization and thermal care of the newborn. In busy Nigerian maternity units, midwives often administer the ointment shortly after the first golden hour or during the initial routine newborn physical examination. If application is delayed due to neonatal resuscitation or immediate maternal complications, the midwife should administer it as soon as the infant is stable, documenting the precise time and reason for any delay.

Potential Side Effects and Transient Reactions

While erythromycin is exceptionally safe, newborns may experience mild, self-limiting local reactions following instillation. The most common side effect is transient chemical conjunctivitis, which presents as mild redness, minor swelling, or temporary blurred vision due to the ointment film over the cornea. These symptoms typically resolve spontaneously within 24 to 48 hours without requiring further medical intervention. Parents should be reassured that these temporary signs are normal and do not indicate a true drug allergy or a lasting eye injury.

Midwifery Documentation and Professional Responsibilities

Accurate record-keeping is an essential legal and clinical duty for midwives practicing in Nigeria. Every administration of neonatal eye prophylaxis must be clearly documented in the baby's health record and the maternity register. Essential details to record include the exact time and date of administration, the specific drug name and concentration (Erythromycin 0.5%), the batch number, and any immediate reactions observed. If parents decline prophylaxis for cultural or personal reasons, the midwife must provide balanced counseling regarding risks, obtain a signed refusal form, and document the discussion thoroughly to ensure professional accountability.